

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Neratinib for treating early hormone receptor-positive,  
HER2-positive breast cancer after adjuvant trastuzumab  
[ID981]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
None identified

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
Not applicable

3. Has any change to the draft scope been agreed to highlight potential equality issues?
Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
None identified

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 15/11/2018